KR101648987B1 - 프로토파낙사디올계 진세노사이드 조성물 및 그의 용도 - Google Patents

프로토파낙사디올계 진세노사이드 조성물 및 그의 용도 Download PDF

Info

Publication number
KR101648987B1
KR101648987B1 KR1020107018644A KR20107018644A KR101648987B1 KR 101648987 B1 KR101648987 B1 KR 101648987B1 KR 1020107018644 A KR1020107018644 A KR 1020107018644A KR 20107018644 A KR20107018644 A KR 20107018644A KR 101648987 B1 KR101648987 B1 KR 101648987B1
Authority
KR
South Korea
Prior art keywords
subject
ginsenoside
composition
acetaldehyde
ginsenosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107018644A
Other languages
English (en)
Korean (ko)
Other versions
KR20100111300A (ko
Inventor
토마스 이. 데일리
마이클 템페스타
Original Assignee
랩터 세라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 랩터 세라퓨틱스 인크. filed Critical 랩터 세라퓨틱스 인크.
Publication of KR20100111300A publication Critical patent/KR20100111300A/ko
Application granted granted Critical
Publication of KR101648987B1 publication Critical patent/KR101648987B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020107018644A 2008-01-24 2009-01-23 프로토파낙사디올계 진세노사이드 조성물 및 그의 용도 Expired - Fee Related KR101648987B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2331008P 2008-01-24 2008-01-24
US61/023,310 2008-01-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167010378A Division KR20160048228A (ko) 2008-01-24 2009-01-23 프로토파낙사디올계 진세노사이드 조성물 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20100111300A KR20100111300A (ko) 2010-10-14
KR101648987B1 true KR101648987B1 (ko) 2016-08-17

Family

ID=40578016

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107018644A Expired - Fee Related KR101648987B1 (ko) 2008-01-24 2009-01-23 프로토파낙사디올계 진세노사이드 조성물 및 그의 용도
KR1020167010378A Withdrawn KR20160048228A (ko) 2008-01-24 2009-01-23 프로토파낙사디올계 진세노사이드 조성물 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167010378A Withdrawn KR20160048228A (ko) 2008-01-24 2009-01-23 프로토파낙사디올계 진세노사이드 조성물 및 그의 용도

Country Status (13)

Country Link
US (1) US8440632B2 (https=)
EP (1) EP2254569B1 (https=)
JP (1) JP5523348B2 (https=)
KR (2) KR101648987B1 (https=)
CN (1) CN101977600B (https=)
AU (1) AU2009206753B2 (https=)
CA (1) CA2713104C (https=)
DK (1) DK2254569T3 (https=)
ES (1) ES2400491T3 (https=)
MY (1) MY160074A (https=)
NZ (1) NZ587134A (https=)
TW (1) TWI440463B (https=)
WO (1) WO2009094177A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190108777A (ko) * 2018-03-15 2019-09-25 숙명여자대학교산학협력단 진세노사이드 Rb1 및 Rb2를 유효성분으로 함유하는 근육 재생용 조성물

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5563285B2 (ja) * 2009-12-14 2014-07-30 ライオン株式会社 飲食品、医薬品、又は医薬部外品、並びに、プロトパナキサトリオールの安定化方法、及びプロトパナキサジオールの安定化方法
WO2013078371A2 (en) 2011-11-22 2013-05-30 The Johns Hopkins University Methods and compositions for reducing alcohol toxicity
KR101446743B1 (ko) * 2012-06-11 2014-10-01 한국생명공학연구원 실리마린을 유효성분으로 포함하는 알콜성 위궤양 예방 및 치료용 조성물
CN102727508B (zh) * 2012-07-15 2014-09-24 浙江大学 人参二醇皂苷组分制备及在防治帕金森氏病中的药物用途
US11338120B2 (en) 2012-08-29 2022-05-24 Palo Alto Investors LP Methods and devices for treating parasympathetic bias mediated conditions
WO2014178803A1 (en) * 2013-04-29 2014-11-06 Alkoçlar Erdal Can A composition for use in the treatment of alcohol addiction
KR101621356B1 (ko) * 2014-09-05 2016-05-17 한국과학기술원 진세노사이드 f2의 간 질환 예방 또는 치료 용도
WO2016066189A1 (en) * 2014-10-28 2016-05-06 Robust Seed Technology A&F Aktiebolag Improved method for seed priming
US10420756B2 (en) * 2015-03-26 2019-09-24 Sen-Jam Pharmaceutical Llc. Methods and compositions to inhibit symptoms associated with veisalgia
KR101641477B1 (ko) * 2016-01-19 2016-07-20 이국진 홍삼 추출물을 이용한 커피나무의 재배방법
CN106619669B (zh) * 2016-12-02 2019-03-29 延边大学 原人参二醇皂苷在制备防治炎症疾病的药物中的应用
CN106511360A (zh) * 2016-12-02 2017-03-22 上海芮范生物科技有限公司 一种含有人参皂苷Rg3和水飞蓟素的组合物及药物
CN112274524A (zh) * 2017-08-24 2021-01-29 浙江大学 人参二醇皂苷Rb组分在制备防治代谢紊乱相关疾病药物中的应用
KR102138252B1 (ko) * 2018-05-16 2020-07-29 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 효모의 nadph 관련 생합성 경로의 개량을 통한 진세노사이드 생산 증대
CN111053782B (zh) * 2018-10-17 2024-07-05 株式会社爱茉莉太平洋 包含人参皂苷的组合物
KR102672902B1 (ko) * 2018-10-31 2024-06-10 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 숙취 해소용 조성물
US11000538B2 (en) * 2018-10-31 2021-05-11 Amorepacific Corporation Composition for enhancing exercise ability or anti-fatigue comprising novel ginsenoside
CN109758464B (zh) * 2019-03-21 2019-10-25 淮阴师范学院 越南人参皂苷r4在制备神经退行性疾病治疗药物中的应用
WO2021069615A1 (en) 2019-10-10 2021-04-15 Zobrius Pharma As Improved anti-hangover composition, its preparation and uses
KR102654669B1 (ko) * 2021-06-30 2024-04-04 경희대학교 산학협력단 실리디아닌을 포함하는 인삼 금 나노에멀젼 및 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1574806A (en) 1976-06-03 1980-09-10 Inverni Della Beffa Spa Production of purified ginseng extracts and pharmaceutical compositions containing the extracts
US4966893A (en) 1989-01-13 1990-10-30 Pang Peter K T Method for treatment of senile dementia
JPH04316448A (ja) 1991-04-12 1992-11-06 Iwatani Internatl Corp 人参微粉末の製造方法
US5547671A (en) 1995-09-20 1996-08-20 Duthinh; Phu Anti-intoxication composition
JP3656972B2 (ja) * 1997-02-14 2005-06-08 丸善製薬株式会社 アルコール臭低減剤
US6083932A (en) 1997-04-18 2000-07-04 Cv Technologies Inc. Pharmaceutical compositions derived from ginseng and methods of treatment using same
US6156291A (en) 1997-08-28 2000-12-05 Cv Technologies Inc. Chemical and pharmacological standardization of herbal extracts
KR20020035855A (ko) 1999-08-30 2002-05-15 마쯔오 미쯔요시 약용인삼을 포함하는 뇌세포 또는 신경세포 보호제
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
CN1167424C (zh) * 2000-11-18 2004-09-22 唐修文 三七人参皂甙肠溶片
US7011096B2 (en) * 2001-08-31 2006-03-14 Philip Morris Usa Inc. Oxidant/catalyst nanoparticles to reduce carbon monoxide in the mainstream smoke of a cigarette
US20030185910A1 (en) 2002-02-08 2003-10-02 Taik Koo Yun Cancer preventive composition comprising ginsenoside glycosides of red ginseng
US6936283B2 (en) 2003-07-25 2005-08-30 Langeland Bjoern T. Composition for stimulation of specific metallo-enzymes
US7186517B2 (en) * 2003-08-01 2007-03-06 Aesgen, Inc. Compositions and methods for monitoring breast cancer treatment
EP1660107A4 (en) * 2003-08-18 2008-06-04 Yuyu Inc GINSENG PREPARATION USING VINEGAR AND MANUFACTURING METHOD THEREFOR
KR20050081247A (ko) * 2004-02-12 2005-08-18 이처준 홍삼 및 흑삼을 이용한 해장국 제조 방법.
WO2005084392A2 (en) * 2004-03-03 2005-09-15 Convivia 4-methylpyrazole formulations for inhibiting ethanol intolerance
KR100547253B1 (ko) 2004-05-29 2006-01-26 박명환 암 예방 및 치료에 유효한 진세노사이드 유도체
CN1698879B (zh) * 2005-06-21 2010-08-11 蔺益民 具有解酒护肝功能的产品及制备方法和用途
CN101232822B (zh) * 2005-07-29 2012-11-14 蒂马基金会 用于减缓乙醇代谢和用于降低乙醇诱导的疾病风险的组合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Lett, Vol.147, No.1-2, pp.77-84(1999.12.01.)*
고려인삼학회지, Vol.15, No.2, pp.106-111(1991.08.)*
고려인삼학회지, Vol.18, No.1, pp.10-16(1994.04.)*

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190108777A (ko) * 2018-03-15 2019-09-25 숙명여자대학교산학협력단 진세노사이드 Rb1 및 Rb2를 유효성분으로 함유하는 근육 재생용 조성물
KR102053208B1 (ko) 2018-03-15 2019-12-06 숙명여자대학교 산학협력단 진세노사이드 Rb1 및 Rb2를 유효성분으로 함유하는 근육 재생용 조성물

Also Published As

Publication number Publication date
DK2254569T3 (da) 2013-02-25
CA2713104A1 (en) 2009-07-30
JP2011510075A (ja) 2011-03-31
JP5523348B2 (ja) 2014-06-18
MY160074A (en) 2017-02-15
EP2254569B1 (en) 2012-11-28
CN101977600A (zh) 2011-02-16
CA2713104C (en) 2016-07-12
HK1144772A1 (en) 2011-03-11
TWI440463B (zh) 2014-06-11
AU2009206753A1 (en) 2009-07-30
EP2254569A1 (en) 2010-12-01
TW200936144A (en) 2009-09-01
ES2400491T3 (es) 2013-04-10
KR20100111300A (ko) 2010-10-14
US20110065659A1 (en) 2011-03-17
WO2009094177A1 (en) 2009-07-30
NZ587134A (en) 2012-04-27
CN101977600B (zh) 2013-02-27
AU2009206753B2 (en) 2014-07-03
US8440632B2 (en) 2013-05-14
KR20160048228A (ko) 2016-05-03

Similar Documents

Publication Publication Date Title
KR101648987B1 (ko) 프로토파낙사디올계 진세노사이드 조성물 및 그의 용도
JP4009642B2 (ja) 肥満改善用組成物
US20070036874A1 (en) Compositions and methods for controlling glucose and lipid uptake from foods
WO2006119038A1 (en) Compositions and methods for controlling glucose uptake
US10183047B2 (en) Chromium-containing compositions in combination with Phyllanthus emblica and shilajit having synergistic effects for improving endothelial function and cardiovascular health
US20230270711A1 (en) Improved Anti-Hangover Composition, Its Preparation and Uses
KR20130027075A (ko) Ｇｌｐ-1 의 분비를 촉진시키고 ｇｉｐ 의 분비를 억제하는 약제
KR102310813B1 (ko) 숙잠 및 효모 추출물을 유효성분으로 함유하는 숙취 해소용 조성물
KR20190063261A (ko) 식물성스테롤(Phytosterols)을 유효성분으로 함유하는 타액 분비 증강 또는 구강건조증 예방 또는 치료용 조성물
US20160015740A1 (en) Chromium-containing compositions for improving endothelial function and cardiovascular health
KR100895500B1 (ko) 호노키올을 유효성분으로 함유하는 지방간 질환의 예방 및치료용 조성물
HK1144772B (en) Protopanaxadiol-type ginsenoside compositions and uses thereof
EP3698786A2 (en) Hangover alleviating composition containing conjugate of sesamol and peptide as active ingredient
US20140328911A1 (en) Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith
CN111773238A (zh) 用于治疗胰岛素抵抗综合征及2型糖尿病的中药制剂
KR20210096121A (ko) 님 추출물의 항당뇨 활성 및 유로리틴 a 및 b의 상승작용적 조합물
JPWO2005082390A1 (ja) 脂肪蓄積抑制剤
KR100612197B1 (ko) 선택적 세로토닌 및 노르에피네프린의 재흡수 억제능을갖는 효모 추출물
JP2007246478A (ja) アセトアルデヒド代謝促進剤
KR20260035105A (ko) 글루타치온 또는 이의 식품학적으로 허용 가능한 염을 포함하는 숙취해소용 식품 조성물
WO2016186695A1 (en) Synergistic compositions containing chromium with phyllanthus emblica and shilajit for improving endothelial function and cardiovascular health
CN121752267A (zh) 针对脂肪分解及/或体重减少的内用组成物、判定有效性的方法、以及植物提取物的质量指标
JP2005200389A (ja) α−グルコシダーゼ阻害剤
JP2008195719A (ja) 血糖値上昇抑制剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190811

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190811